Orphan Designation Fragile X Syndrome
The EC decided the designation of Purposeful’s medicinal product, containing codergocrine mesilate, oxitriptan as an orphan medicinal product for the indication: treatment of fragile X syndrome (EU/3/22/2586).
The EC decided the designation of Purposeful’s medicinal product, containing codergocrine mesilate, oxitriptan as an orphan medicinal product for the indication: treatment of fragile X syndrome (EU/3/22/2586).